Genetic Landscape of SCN1A Variants in a Turkish Cohort with GEFS plus Spectrum and Dravet Syndrome

TÜRKYILMAZ A., Tekin E., Yarali O., ÇEBİ A. H.

MOLECULAR SYNDROMOLOGY, cilt.13, sa.4, ss.270-281, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1159/000521330
  • Dergi Adı: MOLECULAR SYNDROMOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
  • Sayfa Sayıları: ss.270-281
  • Anahtar Kelimeler: Dravet syndrome, Epilepsy, GEFS plus spectrum, Novel variant, SCN1A, SEVERE MYOCLONIC EPILEPSY, FEBRILE SEIZURES PLUS, SODIUM-CHANNEL SCN1A, DE-NOVO MUTATIONS, GENERALIZED EPILEPSY, CLINICAL SPECTRUM, INFANCY, LOCALIZATION, MOSAICISM, NEURONS
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Introduction: The alpha subunit of voltage-gated sodium channels in mammals is encoded by 9 different genes, and variations in the SCN1A, SCN2A, SCN3A, and SCN8A genes highly expressed in the CNS have been associated with epilepsy phenotypes. This study aimed at investigating the frequency of SCN1A gene variations in Dravet syndrome (DS) and GEFS+ spectrum phenotype cases and discussing the molecular results in the context of genotype-phenotype correlation. Methods: Fifteen patients diagnosed with DS and 54 patients meeting the GEFS+ spectrum criteria were included in this study. All patients were evaluated by next-generation sequencing and multiplex ligation-dependent probe amplification using an SCN1A gene commercial kit. Results: A total of 17 different variants were detected in 18 index cases (26%), of which 7 were novel variations (p.M1R, p.M147T, p.I767L, p.N1391Ifs*5, p.R1886G, p.E1915G, p.R1933Q). Of the 18 cases with variation in the SCN1A gene, 12 had DS and 6 had GEFS+ phenotype. The variations were de novo in all DS cases and in 1 case with a GEFS+ phenotype; in 5 GEFS+ cases, the variant was inherited from the affected parent. Discussion: This study contributes to the variation spectrum in cases with DS and GEFS+ phenotype with the novel variants detected. SCN1A genetic analysis can help in determining whether antiseizure medication should be selected or avoided in cases with variations. The elucidation of the molecular etiology makes it possible to provide the family with effective genetic counseling for future pregnancies.